Treating allergic reactions with anti-IgE antibodies
Patent Information
- Application Number
- JP2024534457
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-12-14
- Filing Date
- 2022-12-12
- Publication Date
- 2024-11-29
AI Technical Summary
Current treatments for food allergies, particularly anaphylaxis, are limited, often require regular allergen administration, and do not provide comprehensive protection against accidental exposure, with a significant unmet need for safe and effective therapies, especially for children and adolescents.
Administration of ligelizumab, a humanized monoclonal antibody that binds to IgE with high affinity, blocking its interaction with both high- and low-affinity IgE receptors on mast cells and basophils, thereby reducing allergen sensitivity and preventing allergic reactions.
Ligelizumab effectively suppresses free IgE and basophil FcεRI expression, providing dose- and time-dependent protection against allergic reactions and anaphylaxis, with superior pharmacodynamics compared to omalizumab, allowing for safer and more reliable prevention or treatment of IgE-mediated allergic responses.
Smart Images

Figure 2024544380000001 
Figure 2024544380000002 
Figure 2024544380000003
